As the President of R&D for Keya Medical, Dr. Cao leads the company’s research and development efforts for its medical image analysis product line. Dr. Cao led the development efforts for Keya Medical’s flagship product, DeepVessel FFR, which uses deep learning technology to non-invasively perform a physiological functional assessment of the coronary arteries from coronary computed tomography angiography (CCTA) images.
Keya Medical’s President of R&D, Dr. Kunlin Cao, has been recognized on the 2021 Forbes China Up-and-Coming Businesswomen list. The list highlights 20 accomplished women who have each played a significant role in shaping China’s business landscape through their contributions to technological innovation, scientific achievements, and exemplary leadership.
Dr. Cao has rich experience in medical image analysis that has led to the development of products that improve healthcare delivery. Before joining the company in 2016, Dr. Cao received her Ph.D. in Electrical and Computer Engineering from the University of Iowa and went on to work as a lead scientist in the Biomedical Image Analysis Lab at GE Global Research in New York. Dr. Cao has over ten years of research and development experience in medical image analysis. Her research has focused extensively on image segmentation, image registration, feature extraction, functional information quantification, motion detection, and object localization and tracking for real-time image-guided applications.
In 2020, DeepVessel FFR became the first AI software medical device to receive regulatory clearance from the Chinese National Medical Products Administration. Over the past year, DeepVessel FFR has been implemented in more than 680 hospitals across China, covering nearly 30 million patients.
Keya Medical is proud to have Dr. Cao guiding the company toward creating products that improve patient care delivery worldwide.